D3S-001

PreclinicalSmall molecule

DD3 Bio (Wuxi) Co., Ltd

D3S-001 is one of 78 small molecule programs targeting Solid Tumor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Advanced Solid TumorsRecruiting

Solid TumorPreclinical

Recruiting

Advanced Solid TumorsPreclinical

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Fludara

Sanofi

Preclinical

1 3

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 4

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 5

Soc

Pfizer

Preclinical

1 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 7

Carboplatin AUC-5

Merck & Co.

Preclinical

1 8

SAR445877

Sanofi

Preclinical

1 9

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Preclinical

1 10

Immune Checkpoint Inhibitors

PPeking Union Medical College Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

KRAS P.G12C

NCT05410145

Q3 2028

PreclinicalRecruiting

Solid Tumor

NCT05886920

Clinical

Trials by Indication[1]

Phase 11 trial

A Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Healthy Adult Participants

Completed·DD3 Bio (Wuxi) Co., Ltd·Phase 1·NCT07093398·26 enrolled

KRAS P.G12C1 trial

A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Recruiting·DD3 Bio (Wuxi) Co., Ltd·Preclinical·NCT05410145·442 enrolled

Solid Tumor1 trial

A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Recruiting·DD3 Bio (Wuxi) Co., Ltd·Preclinical·NCT05886920·67 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for D3S-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D3S-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D3S-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — D3 Bio (Wuxi) Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DD3 Bio (Wuxi) Co., Ltd

D3S-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2028

Trials by Indication[1]

Phase 11 trial

KRAS P.G12C1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News